Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Katkhuda covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Viridian Therapeutics, and Dianthus Therapeutics. According to TipRanks, Katkhuda has an average return of 30.9% and a 52.19% success rate on recommended stocks.
Currently, the analyst consensus on Maze Therapeutics, Inc. is a Strong Buy with an average price target of $63.50.
Based on Maze Therapeutics, Inc.’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $20 million and a GAAP net loss of $24.21 million. In comparison, last year the company had a GAAP net loss of $32.79 million
